Search

everythinglearnresearchcommunity

for

Search:↓

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Erlotinib can cause unexpected side effects like eyelash growth and scarring.

Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

Imatinib can cause hair loss due to lichen planopilaris.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

Gefitinib treatment led to unexpected hair growth in two lung cancer patients.

A woman's hair turned white after taking a cancer drug called dasatinib.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.

Upadacitinib improved multiple immune-related conditions in one patient.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Ruxolitinib cream may help treat severe hair loss in children.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.